VHH single-domain antibodies are increasingly being used as modular building blocks in next-generation biologics. Their small size, stability and engineering flexibility mean they can be “bolted on” to other therapeutic molecules to add new functionality — from extending half-life and improving targeting to enabling bi-specific, multi-specific and intracellular applications.
In the full article, Isogenica explores how VHHs can be used to build smarter therapeutic formats by adding specific capabilities to existing or emerging biologic designs. The blog looks at areas such as albumin-binding VHHs for half-life extension, VHHs in bi- and multi-specific engineering, and intracellular applications including targeted protein degradation.
The article highlights why modularity matters. Because VHHs are compact, soluble and engineerable, they can be combined with other antibody domains or therapeutic scaffolds to create formats that engage more than one target, improve tissue penetration or support more flexible protein engineering strategies.
Overall, the blog positions VHHs as more than standalone binders. They are adaptable engineering modules that can help improve the performance, targeting and developability of advanced therapeutics.
Read the full blog: https://isogenica.com/building-smarter-therapeutics-with-vhh-bolt-ons/